EV Bubble Watch on Rivian and Tesla
In 2025, the performance of electric vehicle stocks is mixed. Rivian Automotive (RIVN) is performing the best in a trading range of between $12 - $14. Tesla (TSLA) gave up half of its post-presidential election gain while Lucid Group (LCID) risks retreating to the $2.00 low.On Feb. 20, Rivian posted a positive gross margin in its fourth-quarter earnings report. The EV truck supplier cut costs by $31,000 per unit. Cost controls, average selling prices, and higher regulatory credit revenue helped results.Rivian’s tri-motor launch is a bullish catalyst. In addition, the R2 program launch is scheduled for the first half of 2026. Rivian ended Q4 with plenty of cash on hand at $7.7 billion. It received $2.3 billion in funding from Volkswagen Group (VWAGY).Rivian is the most attractive EV stock compared to Tesla or Lucid. Bears hold a commanding 8.31% short interest against Lucid stock. CEO Elon Musk’s leadership in DOGE – Department of Government Efficiency – is hurting Tesla sales. Musk’s political affiliation divides consumers. Those who do not support his politics are avoiding Tesla vehicles.Despite weaker sales ahead, firms like Nissan (NSANY) are seeking Tesla as a strategic investor. Before that, merger talks between Nissan and Honda (HMC) broke down. Given Nissan’s junk rating, Tesla shareholders should not support any involvement with the firm.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


